Modality
Vaccine
MOA
CD3xCD20
Target
JAK1
Pathway
PI3K/AKT
MigraineAMLCRC
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
Jun 2018
→ Feb 2029
Phase 2Current
NCT05667466
2,734 pts·Migraine
2023-09→2029-02·Recruiting
NCT05778583
1,234 pts·Migraine
2018-06→2025-04·Completed
3,968 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-2211mo agoPh3 Readout· Migraine
2029-02-082.9y awayPh3 Readout· Migraine
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Complet…
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-04-22 · 11mo ago
Migraine
Ph3 Readout
2029-02-08 · 2.9y away
Migraine
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05667466 | Phase 2/3 | Migraine | Recruiting | 2734 | FEV1 |
| NCT05778583 | Phase 2/3 | Migraine | Completed | 1234 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |